Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Lung Cancer. 30 results shown below.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy

[Complete title: Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers]
Principal Investigator: Jing Zeng
Study Number: 9148
Phase: Pilot

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

[Complete title: A Pilot Study of MPDL3280A (PD-L1 Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients with Metastatic Non-Small Cell Lung Cancer (UMCC 2015.005)]
Principal Investigator: Ramesh Rengan
Study Number: 9490
Phase: Pilot

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

[Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)]
Principal Investigator: Jing Zeng
Study Number: 9599
Phase: II

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

[Complete title: Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor]
Principal Investigator: Sylvia Lee, MD
Study Number: 2727.00
Phase: I/II

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

[Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Rafael Santana-Davila
Study Number: A081105
Phase: III

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

[Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)]
Principal Investigator: Rafael Santana-Davila
Study Number: A151216
Phase: NA

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

[Complete title: A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody in Combination with Sargramostim in Patients with Recurrent Osteosarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AOST1421
Phase: II

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

[Complete title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein]
Principal Investigator: Rafael Santana-Davila
Study Number: E4512
Phase: III

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

[Complete title: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC]
Principal Investigator: Ramesh Rengan
Study Number: RTOG 1308
Phase: III

Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

[Complete title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer]
Principal Investigator: Christina Baik
Study Number: S1400
Phase: II/III

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

[Complete title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 20131955
Phase: I/II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

[Complete title: A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20141860
Phase: I

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

[Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20150094
Phase: I

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

[Complete title: A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges]
Principal Investigator: Christina Baik
Study Number: 20150427
Phase: II

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

[Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20150645
Phase: I/II

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

[Complete title: A Phase 1 exploratory study of the safety and ex vivo fluorescence of BLZ-100 administered by intravenous injection in adult subjects with solid tumors undergoing surgery.]
Principal Investigator: David Byrd, MD
Study Number: 20151060
Phase: I

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

[Complete title: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20151071
Phase: II

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium

[Complete title: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium]
Principal Investigator: Rafael Santana-Davila
Study Number: 20151222
Phase: I

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

[Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20151522
Phase: I

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

[Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements]
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

[Complete title: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ROVALPITUZUMAB TESIRINE (SC16LD6.5) FOR THIRD-LINE AND LATER TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY DELTA-LIKE PROTEIN 3-EXPRESSING SMALL CELL LUNG CANCER (TRINITY)]
Principal Investigator: Rafael Santana-Davila
Study Number: 20152704
Phase: II

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

[Complete title: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies]
Principal Investigator: Ryan Cassaday
Study Number: 20152763
Phase: I

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer [IMpower 132]

[Complete title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER]
Principal Investigator: Rafael Santana-Davila
Study Number: 20160241
Phase: III

A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

[Complete title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)]
Principal Investigator: Laura Chow
Study Number: 20161065
Phase: II

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials